RxDoctor Payments Data

Thomas Masterson, MD

Internal Medicine · Clinton, MDNPI 1649224643

Payments from drug & device makers

$798in general payments, 2019–2025

Across 12 payments — averaging $66.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$367
  • Avanir Pharmaceuticals, Inc.$125
  • Boehringer Ingelheim$111
  • Philips North America LLC$94
  • AstraZeneca$72
  • Urovant Sciences Inc$29

What the payments were for

  • Food & beverage$798100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$798 in reported general payments places this provider in the 70th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$317,261
Medicare patients
835
Services billed
3,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban772$258,820
Avonex (4 Pack)Interferon Beta-1a13$114,526
NuplazidPimavanserin Tartrate47$110,457
BiktarvyBictegrav/Emtricit/Tenofov Ala23$96,079
XifaxanRifaximin27$41,370
TivicayDolutegravir Sodium31$38,591
JardianceEmpagliflozin92$35,015
Sevelamer Carbonate119$21,471
TradjentaLinagliptin51$21,251
OxycontinOxycodone Hcl21$20,747
VelphoroSucroferric Oxyhydroxide12$20,722
XareltoRivaroxaban71$20,058
SantylCollagenase Clostridium Hist.14$19,960
OzempicSemaglutide19$19,822
TrulicityDulaglutide34$19,197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$367$110,45747 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$111$68,785167 claims
AstraZenecaLokelma, Brilinta$72$19,83362 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Clinton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →